Literature DB >> 25048193

The sterol-based transcriptional control of human 7-dehydrocholesterol reductase (DHCR7): Evidence of a cooperative regulatory program in cholesterol synthesis.

Anika V Prabhu1, Laura J Sharpe1, Andrew J Brown2.   

Abstract

The enzyme 7-dehydrocholesterol reductase (DHCR7) catalyzes the final step of cholesterol synthesis via the Kandutsch-Russell pathway, and is crucial in maintaining cellular cholesterol levels. Its absence leads to the devastating fetal developmental disorder Smith-Lemli-Opitz Syndrome (SLOS). How this enzyme is regulated has implications in controlling not only cholesterol synthesis, but also the synthesis of Vitamin D - another product of 7-dehydrocholesterol. In this study, we look specifically at how DHCR7 is regulated by the sterol regulatory element-binding protein-2 (SREBP-2) transcription factor. Sterol regulation has previously been studied in the rat DHCR7 promoter, but we have found that its regulatory elements are not all conserved in humans. Rather, the human promoter contains two binding sites for SREBP-2 (at -155 and -55) and a binding site for the nuclear factor-Y (NF-Y) cofactor (at -136). The -155 site is a particularly responsive sterol regulatory element (SRE) which is well conserved in mammals, and was possibly overlooked in the rat promoter study. The exact location of the weaker -55 site (close to the known rat SRE) may have shifted during evolution. Furthermore, we established that the two SREs that bind SREBP-2 work in cooperation to synergistically activate DHCR7. We have previously characterized the SREs in DHCR24, the final enzyme in the alternate Bloch pathway of cholesterol synthesis. Here, comparison of the sterol regulation of these terminal enzymes demonstrates the unique cooperative system that helps to control cholesterol synthesis.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cooperativity; DHCR7; NF-Y; SRE; SREBP-2; Transcription regulation

Year:  2014        PMID: 25048193     DOI: 10.1016/j.bbalip.2014.07.006

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  15 in total

1.  The terminal enzymes of cholesterol synthesis, DHCR24 and DHCR7, interact physically and functionally.

Authors:  Winnie Luu; Gene Hart-Smith; Laura J Sharpe; Andrew J Brown
Journal:  J Lipid Res       Date:  2015-01-31       Impact factor: 5.922

2.  Non-canonical ubiquitination of the cholesterol-regulated degron of squalene monooxygenase.

Authors:  Ngee Kiat Chua; Gene Hart-Smith; Andrew J Brown
Journal:  J Biol Chem       Date:  2019-04-02       Impact factor: 5.157

3.  Twin enzymes, divergent control: The cholesterogenic enzymes DHCR14 and LBR are differentially regulated transcriptionally and post-translationally.

Authors:  Isabelle M Capell-Hattam; Laura J Sharpe; Lydia Qian; Gene Hart-Smith; Anika V Prabhu; Andrew J Brown
Journal:  J Biol Chem       Date:  2020-01-07       Impact factor: 5.157

Review 4.  Cancer prevention and therapy through the modulation of the tumor microenvironment.

Authors:  Stephanie C Casey; Amedeo Amedei; Katia Aquilano; Asfar S Azmi; Fabian Benencia; Dipita Bhakta; Alan E Bilsland; Chandra S Boosani; Sophie Chen; Maria Rosa Ciriolo; Sarah Crawford; Hiromasa Fujii; Alexandros G Georgakilas; Gunjan Guha; Dorota Halicka; William G Helferich; Petr Heneberg; Kanya Honoki; W Nicol Keith; Sid P Kerkar; Sulma I Mohammed; Elena Niccolai; Somaira Nowsheen; H P Vasantha Rupasinghe; Abbas Samadi; Neetu Singh; Wamidh H Talib; Vasundara Venkateswaran; Richard L Whelan; Xujuan Yang; Dean W Felsher
Journal:  Semin Cancer Biol       Date:  2015-04-10       Impact factor: 15.707

5.  Cholesterol-mediated Degradation of 7-Dehydrocholesterol Reductase Switches the Balance from Cholesterol to Vitamin D Synthesis.

Authors:  Anika V Prabhu; Winnie Luu; Laura J Sharpe; Andrew J Brown
Journal:  J Biol Chem       Date:  2016-02-17       Impact factor: 5.157

6.  Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.

Authors:  Sam J L van der Tuin; Susan Kühnast; Jimmy F P Berbée; Lars Verschuren; Elsbet J Pieterman; Louis M Havekes; José W A van der Hoorn; Patrick C N Rensen; J Wouter Jukema; Hans M G Princen; Ko Willems van Dijk; Yanan Wang
Journal:  J Lipid Res       Date:  2015-09-04       Impact factor: 5.922

7.  Quantitative proteomic analysis reveals that anti-cancer effects of selenium-binding protein 1 in vivo are associated with metabolic pathways.

Authors:  Qi Ying; Emmanuel Ansong; Alan M Diamond; Zhaoxin Lu; Wancai Yang; Xiaomei Bie
Journal:  PLoS One       Date:  2015-05-14       Impact factor: 3.240

Review 8.  Targeting Smoothened as a New Frontier in the Functional Recovery of Central Nervous System Demyelinating Pathologies.

Authors:  Alice Del Giovane; Antonella Ragnini-Wilson
Journal:  Int J Mol Sci       Date:  2018-11-20       Impact factor: 5.923

9.  NF-Y activates genes of metabolic pathways altered in cancer cells.

Authors:  Paolo Benatti; Maria Luisa Chiaramonte; Mariangela Lorenzo; John A Hartley; Daniel Hochhauser; Nerina Gnesutta; Roberto Mantovani; Carol Imbriano; Diletta Dolfini
Journal:  Oncotarget       Date:  2016-01-12

10.  Activation of Sterol Regulatory Element Binding Factors by Fenofibrate and Gemfibrozil Stimulates Myelination in Zebrafish.

Authors:  Yoshifumi Ashikawa; Yuhei Nishimura; Shiko Okabe; Shota Sasagawa; Soichiro Murakami; Mizuki Yuge; Koki Kawaguchi; Reiko Kawase; Toshio Tanaka
Journal:  Front Pharmacol       Date:  2016-07-11       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.